Cargando…

The effect of tocilizumab on cytokine release syndrome in COVID-19 patients

BACKGROUND: This study was aimed to assess the efficacy and safety of tocilizumab (TCZ) and to investigate the factors related to the progress and mortality of patients with a secondary cytokine release syndrome caused by SARS-CoV-2. METHODS: A retrospective descriptive observational study of hospit...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Cáceres, Carmen, Martínez, Rodrigo, Bachiller, Pablo, Marín, Laura, García, José Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650573/ https://www.ncbi.nlm.nih.gov/pubmed/33165762 http://dx.doi.org/10.1007/s43440-020-00186-z

Ejemplares similares

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
por: Hassoun, Ali, et al.
Publicado: (2020)

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
por: Uslu, Sadettin
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome()
por: Velasco Puyó, Pablo, et al.
Publicado: (2020)

Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers
por: Nasa, Prashant, et al.
Publicado: (2020)

Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report
por: Radbel, Jared, et al.
Publicado: (2020)

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
por: Liu, Danfei, et al.
Publicado: (2020)

Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan
por: Hassan, Muhammad, et al.
Publicado: (2021)

Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study
por: Mastroianni, Antonio, et al.
Publicado: (2020)

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
por: Sarhan, Neven Mohamed, et al.
Publicado: (2023)

Influence of Cytokine Release Syndrome in Severe COVID-19 Patients Treated With Tocilizumab Over the Quantiferon TB Gold Plus Results
por: Sánchez-Martínez, Francesca, et al.
Publicado: (2021)

Case Study: A Patient with Asthma, Covid-19 Pneumonia and Cytokine Release Syndrome Treated with Corticosteroids and Tocilizumab
por: Schleicher, Gunter K, et al.
Publicado: (2020)

Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome
por: Ali, Sabahat, et al.
Publicado: (2021)

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
por: Antinori, Spinello, et al.
Publicado: (2020)

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
por: Zhang, Chi, et al.
Publicado: (2020)

Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients
por: Xu, Lengnan, et al.
Publicado: (2022)

Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19
por: Saha, Abinit, et al.
Publicado: (2020)

Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome
por: Oliynyk, Oleksandr, et al.
Publicado: (2021)

Can tocilizumab calm the cytokine storm of COVID-19?
por: Schulert, Grant S
Publicado: (2020)

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
por: Si, Stephanie, et al.
Publicado: (2020)

Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab
por: Gautier-Vargas, Gabriela, et al.
Publicado: (2020)

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
por: Price, Christina C., et al.
Publicado: (2020)

“Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience”, a retrospective study-original article
por: Chachar, Aijaz Zeeshan Khan, et al.
Publicado: (2021)

Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India
por: Dravid, Ameet, et al.
Publicado: (2021)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
por: Langer-Gould, Annette, et al.
Publicado: (2020)

Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy
por: Lebedeva, Anna, et al.
Publicado: (2022)

Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series
por: Nakamura, Hideta, et al.
Publicado: (2020)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

A Validated Mathematical Model of the Cytokine Release Syndrome in Severe COVID-19
por: Reis, Ruy Freitas, et al.
Publicado: (2021)

The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers
por: Rubio-Rivas, Manuel, et al.
Publicado: (2021)

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
por: Le, Robert Q., et al.
Publicado: (2018)

Tocilizumab and COVID-19
por: Chaudhry, Dhruva, et al.
Publicado: (2020)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

The Treatment of COVID-19 Purgatory Syndrome With Tocilizumab and Steroids
por: Selvaraj, Vijairam, et al.
Publicado: (2022)

Role of Tocilizumab in the Treatment of COVID-19 Patients with Cytokine Storm: A Case Series
por: Basnet, Ajaya, et al.
Publicado: (2022)

Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia—A Retrospective Study
por: Chober, Daniel, et al.
Publicado: (2022)

P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Editorial: Cytokine Release Syndrome in COVID-19: Mechanisms and Management
por: Hu, Tao
Publicado: (2022)

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series
por: Yang, Stephen Su, et al.
Publicado: (2021)

Tocilizumab en el paciente con COVID-19
por: Sancho, Milagros, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s81ga2monc2ja54fkgnfava8n5